Skip to main content
. Author manuscript; available in PMC: 2019 Oct 15.
Published in final edited form as: Clin Cancer Res. 2018 Jul 3;24(20):5085–5097. doi: 10.1158/1078-0432.CCR-18-0873

Figure 4. Regression of cutaneous KS lesions in a HIV+KS+ patient treated with MC-specific anti-inflammatory therapy.

Figure 4.

Serial sections of lesion biopsy were stained (A-D); A) H&E, (B) IHC LANA staining indicating presence of KSHV, (C) MC specific tryptase shows extensive infiltration and activation, (D) MCs in lesions are CD117/c-Kit positive. (E) Visible lesion regression on right leg (top row) and left foot (bottom row) at Day 14, 29 and 64 post-initiation of anti-MC treatment.